Cargando…
Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium
BACKGROUND: Multisystem inflammatory syndrome in children (MIS-C) is a severe complication of SARS-CoV-2 infection. It remains unclear how MIS-C phenotypes vary across SARS-CoV-2 variants. We aimed to investigate clinical characteristics and outcomes of MIS-C across SARS-CoV-2 eras. METHODS: We perf...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511777/ https://www.ncbi.nlm.nih.gov/pubmed/37745025 http://dx.doi.org/10.1016/j.eclinm.2023.102212 |
_version_ | 1785108217048596480 |
---|---|
author | Sperotto, Francesca Gutiérrez-Sacristán, Alba Makwana, Simran Li, Xiudi Rofeberg, Valerie N. Cai, Tianxi Bourgeois, Florence T. Omenn, Gilbert S. Hanauer, David A. Sáez, Carlos Bonzel, Clara-Lea Bucholz, Emily Dionne, Audrey Elias, Matthew D. García-Barrio, Noelia González, Tomás González Issitt, Richard W. Kernan, Kate F. Laird-Gion, Jessica Maidlow, Sarah E. Mandl, Kenneth D. Ahooyi, Taha Mohseni Moraleda, Cinta Morris, Michele Moshal, Karyn L. Pedrera-Jiménez, Miguel Shah, Mohsin A. South, Andrew M. Spiridou, Anastasia Taylor, Deanne M. Verdy, Guillaume Visweswaran, Shyam Wang, Xuan Xia, Zongqi Zachariasse, Joany M. Newburger, Jane W. Avillach, Paul |
author_facet | Sperotto, Francesca Gutiérrez-Sacristán, Alba Makwana, Simran Li, Xiudi Rofeberg, Valerie N. Cai, Tianxi Bourgeois, Florence T. Omenn, Gilbert S. Hanauer, David A. Sáez, Carlos Bonzel, Clara-Lea Bucholz, Emily Dionne, Audrey Elias, Matthew D. García-Barrio, Noelia González, Tomás González Issitt, Richard W. Kernan, Kate F. Laird-Gion, Jessica Maidlow, Sarah E. Mandl, Kenneth D. Ahooyi, Taha Mohseni Moraleda, Cinta Morris, Michele Moshal, Karyn L. Pedrera-Jiménez, Miguel Shah, Mohsin A. South, Andrew M. Spiridou, Anastasia Taylor, Deanne M. Verdy, Guillaume Visweswaran, Shyam Wang, Xuan Xia, Zongqi Zachariasse, Joany M. Newburger, Jane W. Avillach, Paul |
author_sort | Sperotto, Francesca |
collection | PubMed |
description | BACKGROUND: Multisystem inflammatory syndrome in children (MIS-C) is a severe complication of SARS-CoV-2 infection. It remains unclear how MIS-C phenotypes vary across SARS-CoV-2 variants. We aimed to investigate clinical characteristics and outcomes of MIS-C across SARS-CoV-2 eras. METHODS: We performed a multicentre observational retrospective study including seven paediatric hospitals in four countries (France, Spain, U.K., and U.S.). All consecutive confirmed patients with MIS-C hospitalised between February 1st, 2020, and May 31st, 2022, were included. Electronic Health Records (EHR) data were used to calculate pooled risk differences (RD) and effect sizes (ES) at site level, using Alpha as reference. Meta-analysis was used to pool data across sites. FINDINGS: Of 598 patients with MIS-C (61% male, 39% female; mean age 9.7 years [SD 4.5]), 383 (64%) were admitted in the Alpha era, 111 (19%) in the Delta era, and 104 (17%) in the Omicron era. Compared with patients admitted in the Alpha era, those admitted in the Delta era were younger (ES −1.18 years [95% CI −2.05, −0.32]), had fewer respiratory symptoms (RD −0.15 [95% CI −0.33, −0.04]), less frequent non-cardiogenic shock or systemic inflammatory response syndrome (SIRS) (RD −0.35 [95% CI −0.64, −0.07]), lower lymphocyte count (ES −0.16 × 10(9)/uL [95% CI −0.30, −0.01]), lower C-reactive protein (ES −28.5 mg/L [95% CI −46.3, −10.7]), and lower troponin (ES −0.14 ng/mL [95% CI −0.26, −0.03]). Patients admitted in the Omicron versus Alpha eras were younger (ES −1.6 years [95% CI −2.5, −0.8]), had less frequent SIRS (RD −0.18 [95% CI −0.30, −0.05]), lower lymphocyte count (ES −0.39 × 10(9)/uL [95% CI −0.52, −0.25]), lower troponin (ES −0.16 ng/mL [95% CI −0.30, −0.01]) and less frequently received anticoagulation therapy (RD −0.19 [95% CI −0.37, −0.04]). Length of hospitalization was shorter in the Delta versus Alpha eras (−1.3 days [95% CI −2.3, −0.4]). INTERPRETATION: Our study suggested that MIS-C clinical phenotypes varied across SARS-CoV-2 eras, with patients in Delta and Omicron eras being younger and less sick. EHR data can be effectively leveraged to identify rare complications of pandemic diseases and their variation over time. FUNDING: None. |
format | Online Article Text |
id | pubmed-10511777 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-105117772023-09-22 Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium Sperotto, Francesca Gutiérrez-Sacristán, Alba Makwana, Simran Li, Xiudi Rofeberg, Valerie N. Cai, Tianxi Bourgeois, Florence T. Omenn, Gilbert S. Hanauer, David A. Sáez, Carlos Bonzel, Clara-Lea Bucholz, Emily Dionne, Audrey Elias, Matthew D. García-Barrio, Noelia González, Tomás González Issitt, Richard W. Kernan, Kate F. Laird-Gion, Jessica Maidlow, Sarah E. Mandl, Kenneth D. Ahooyi, Taha Mohseni Moraleda, Cinta Morris, Michele Moshal, Karyn L. Pedrera-Jiménez, Miguel Shah, Mohsin A. South, Andrew M. Spiridou, Anastasia Taylor, Deanne M. Verdy, Guillaume Visweswaran, Shyam Wang, Xuan Xia, Zongqi Zachariasse, Joany M. Newburger, Jane W. Avillach, Paul eClinicalMedicine Articles BACKGROUND: Multisystem inflammatory syndrome in children (MIS-C) is a severe complication of SARS-CoV-2 infection. It remains unclear how MIS-C phenotypes vary across SARS-CoV-2 variants. We aimed to investigate clinical characteristics and outcomes of MIS-C across SARS-CoV-2 eras. METHODS: We performed a multicentre observational retrospective study including seven paediatric hospitals in four countries (France, Spain, U.K., and U.S.). All consecutive confirmed patients with MIS-C hospitalised between February 1st, 2020, and May 31st, 2022, were included. Electronic Health Records (EHR) data were used to calculate pooled risk differences (RD) and effect sizes (ES) at site level, using Alpha as reference. Meta-analysis was used to pool data across sites. FINDINGS: Of 598 patients with MIS-C (61% male, 39% female; mean age 9.7 years [SD 4.5]), 383 (64%) were admitted in the Alpha era, 111 (19%) in the Delta era, and 104 (17%) in the Omicron era. Compared with patients admitted in the Alpha era, those admitted in the Delta era were younger (ES −1.18 years [95% CI −2.05, −0.32]), had fewer respiratory symptoms (RD −0.15 [95% CI −0.33, −0.04]), less frequent non-cardiogenic shock or systemic inflammatory response syndrome (SIRS) (RD −0.35 [95% CI −0.64, −0.07]), lower lymphocyte count (ES −0.16 × 10(9)/uL [95% CI −0.30, −0.01]), lower C-reactive protein (ES −28.5 mg/L [95% CI −46.3, −10.7]), and lower troponin (ES −0.14 ng/mL [95% CI −0.26, −0.03]). Patients admitted in the Omicron versus Alpha eras were younger (ES −1.6 years [95% CI −2.5, −0.8]), had less frequent SIRS (RD −0.18 [95% CI −0.30, −0.05]), lower lymphocyte count (ES −0.39 × 10(9)/uL [95% CI −0.52, −0.25]), lower troponin (ES −0.16 ng/mL [95% CI −0.30, −0.01]) and less frequently received anticoagulation therapy (RD −0.19 [95% CI −0.37, −0.04]). Length of hospitalization was shorter in the Delta versus Alpha eras (−1.3 days [95% CI −2.3, −0.4]). INTERPRETATION: Our study suggested that MIS-C clinical phenotypes varied across SARS-CoV-2 eras, with patients in Delta and Omicron eras being younger and less sick. EHR data can be effectively leveraged to identify rare complications of pandemic diseases and their variation over time. FUNDING: None. Elsevier 2023-09-14 /pmc/articles/PMC10511777/ /pubmed/37745025 http://dx.doi.org/10.1016/j.eclinm.2023.102212 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Articles Sperotto, Francesca Gutiérrez-Sacristán, Alba Makwana, Simran Li, Xiudi Rofeberg, Valerie N. Cai, Tianxi Bourgeois, Florence T. Omenn, Gilbert S. Hanauer, David A. Sáez, Carlos Bonzel, Clara-Lea Bucholz, Emily Dionne, Audrey Elias, Matthew D. García-Barrio, Noelia González, Tomás González Issitt, Richard W. Kernan, Kate F. Laird-Gion, Jessica Maidlow, Sarah E. Mandl, Kenneth D. Ahooyi, Taha Mohseni Moraleda, Cinta Morris, Michele Moshal, Karyn L. Pedrera-Jiménez, Miguel Shah, Mohsin A. South, Andrew M. Spiridou, Anastasia Taylor, Deanne M. Verdy, Guillaume Visweswaran, Shyam Wang, Xuan Xia, Zongqi Zachariasse, Joany M. Newburger, Jane W. Avillach, Paul Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium |
title | Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium |
title_full | Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium |
title_fullStr | Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium |
title_full_unstemmed | Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium |
title_short | Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium |
title_sort | clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across sars-cov-2 variant eras: a multinational study from the 4ce consortium |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511777/ https://www.ncbi.nlm.nih.gov/pubmed/37745025 http://dx.doi.org/10.1016/j.eclinm.2023.102212 |
work_keys_str_mv | AT sperottofrancesca clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT gutierrezsacristanalba clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT makwanasimran clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT lixiudi clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT rofebergvalerien clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT caitianxi clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT bourgeoisflorencet clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT omenngilberts clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT hanauerdavida clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT saezcarlos clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT bonzelclaralea clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT bucholzemily clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT dionneaudrey clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT eliasmatthewd clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT garciabarrionoelia clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT gonzaleztomasgonzalez clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT issittrichardw clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT kernankatef clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT lairdgionjessica clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT maidlowsarahe clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT mandlkennethd clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT ahooyitahamohseni clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT moraledacinta clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT morrismichele clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT moshalkarynl clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT pedrerajimenezmiguel clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT shahmohsina clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT southandrewm clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT spiridouanastasia clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT taylordeannem clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT verdyguillaume clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT visweswaranshyam clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT wangxuan clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT xiazongqi clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT zachariassejoanym clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT newburgerjanew clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium AT avillachpaul clinicalphenotypesandoutcomesinchildrenwithmultisysteminflammatorysyndromeacrosssarscov2varianterasamultinationalstudyfromthe4ceconsortium |